Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rationale: Extracts of the plant Salvia miltiorrhiza (Danshen) have been used as traditional Chinese medicine in the treatment of cardiovascular diseases, such as angina pectoris and myocardial infarction. Several preclinical studies point towards promising effects of Danshen on risk factors of atherosclerotic cardiovascular diseases, such as hyperlipidemia and hypertension.
Objective: Our primary objective is to determine the effect of Salvia miltiorrhiza extract (Danshen) on hyperlipidemia. Secondary objective is to investigate the effect of Danshen on hypertension. Further objectives are to determine its effect on endothelial function, oxidative stress, inflammation, hemostasis and hemorheology, and on insulin sensitivity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Salvia miltiorrhiza extract (Danshen) | Experimental | p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks |
|
| placebo | Placebo Comparator | p.o. placebo, twice daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Salvia miltiorrhiza extract | Dietary Supplement | 3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hyperlipidemia | Blood tests: lipids, in particular LDL-cholesterol. | after 4 weeks of treatment with Danshen |
| Measure | Description | Time Frame |
|---|---|---|
| Hypertension | after 4 weeks of treatment with Danshen | |
| Endothelial function | after 4 weeks of treatment with Danshen | |
| Plasma markers of oxidative stress |
Not provided
Inclusion Criteria:
Age: 40-70
Women:
Hyperlipidemia:
Hypertension:
Signed informed consent
Exclusion Criteria:
Alcohol or drug abuse
History of cardiovascular disease (myocard infarct, angina pectoris, CVA)
Diabetes mellitus, when treated with insulin
Pregnancy
Hyperlipidemia which needs conventional treatment
Hypertension which needs conventional treatment:
Clinically significant liver disease (3 times the upper normal limit of ALAT,ASAT)
Clinically significant anemia (male Hb < 6,9 mmol/L, female < 6,25 mmol/L)
Renal disease defined as MDRD < 60 ml/min/1.73m2
Participation to any drug-investigation during the previous 90 days
Use of any herbal product during the previous 30 days
Concomitant (chronic) use of:
Medicinal products:
Food products:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pauline Breedveld, PhD | Contact | +31243614597 | p.breedveld@pharmtox.umcn.nl | |
| Pleun van Poppel, MD | Contact | +31243667211 | p.vanpoppel@aig.umcn.nl |
| Name | Affiliation | Role |
|---|---|---|
| Gerard Rongen, MD, PhD, Professor | Radboud University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboud University Nijmegen Medical Centre | Recruiting | Nijmegen | 6500 HB | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26192328 | Derived | van Poppel PC, Breedveld P, Abbink EJ, Roelofs H, van Heerde W, Smits P, Lin W, Tan AH, Russel FG, Donders R, Tack CJ, Rongen GA. Salvia Miltiorrhiza Root Water-Extract (Danshen) Has No Beneficial Effect on Cardiovascular Risk Factors. A Randomized Double-Blind Cross-Over Trial. PLoS One. 2015 Jul 20;10(7):e0128695. doi: 10.1371/journal.pone.0128695. eCollection 2015. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D006973 | Hypertension |
| D000783 | Aneurysm |
| D007249 | Inflammation |
| D006949 | Hyperlipidemias |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C028972 | dan-shen root extract |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | 3 placebo capsules, twice daily for four consecutive weeks |
|
| after 4 weeks of treatment with Danshen |
| Vascular inflammation and inflammatory activation of adipose tissue | after 4 weeks of treatment with danshen |
| Hemostasis and hemorheological parameters | after 4 weeks of treatment with Danshen |
| Insulin sensitivity | after 4 weeks of treatment with Danshen |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |